ADVANCING AMERICAN KIDNEY HEALTH IS FOCUSING ON PATIENT CHOICES; IMPROVING THEIR CHOICES TO HAVE MORE HOME DIALYSIS THERAPIES, MORE TRANSPLANTS. We know from the research that quality of life does improve with these treatments. I really think we can move the field forward in terms of improving the lives of patients with kidney disease.

Nwamaka D. Eneanya, MD, MPH, FASN
University of Pennsylvania
Philadelphia, PA
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Message From Executive Leadership Team</td>
<td>4</td>
</tr>
<tr>
<td>Letter from Mark E. Rosenberg, MD, FASN, and Anupam Agarwal, MD, FASN</td>
<td></td>
</tr>
<tr>
<td>ASN Council</td>
<td>5</td>
</tr>
<tr>
<td>Excellence in Patient Care</td>
<td>6</td>
</tr>
<tr>
<td>Research, Discovery, and Innovation</td>
<td>9</td>
</tr>
<tr>
<td>Education and Information</td>
<td>11</td>
</tr>
<tr>
<td>Leadership Development and Culture Change</td>
<td>14</td>
</tr>
<tr>
<td>Policy and Advocacy</td>
<td>16</td>
</tr>
<tr>
<td>ASN Award Recipients</td>
<td>18</td>
</tr>
<tr>
<td>KidneyCure Grant Recipient Spotlight</td>
<td>20</td>
</tr>
<tr>
<td>KidneyCure Grant Recipients</td>
<td>21</td>
</tr>
<tr>
<td>Founders Circle Members</td>
<td>28</td>
</tr>
<tr>
<td>KidneyCure Supporters</td>
<td>29</td>
</tr>
<tr>
<td>Consolidated Financials</td>
<td>31</td>
</tr>
<tr>
<td>Financial Snapshot 2010–2019</td>
<td>32</td>
</tr>
<tr>
<td>Performance in 2019</td>
<td>33</td>
</tr>
<tr>
<td>ASN Sources of Revenue</td>
<td>34</td>
</tr>
<tr>
<td>ASN Sources of Expenses</td>
<td>35</td>
</tr>
<tr>
<td>Organizational Snapshot</td>
<td>36</td>
</tr>
<tr>
<td>Financial Dashboard</td>
<td>37</td>
</tr>
<tr>
<td>Corporate Supporters</td>
<td>38</td>
</tr>
</tbody>
</table>
MESSAGE FROM THE EXECUTIVE LEADERSHIP TEAM

Dear Colleagues,

The year 2019 saw unprecedented developments in kidney care, research, and education for patients and health professionals. ASN has been at the forefront of these developments.

In July, the Executive Order on Advancing American Kidney Health was signed. The initiative is starting to make sweeping changes to care for people with kidney diseases, including a focus on slowing the progression of kidney diseases, expanding options for dialysis modalities, increasing access to kidney transplantation, and accelerating support for development of innovative therapies.

Additionally, ASN introduced its new brand identity, featuring a logo signifying the patient as the center of focus, interconnected with clinicians, researchers, and educators, as well as related logos for all ASN Alliance entities. The new brand identity aligns well with the *ASN Alliance for Kidney Health: Proposed Vision in 2030*, which the leadership finalized in 2019.

In this annual report, we present ASN’s accomplishments for 2019, grouped according to five of the ASN Alliance for Kidney Health’s areas of focus.

Kidney health has become a national priority in the United States, and the ASN Alliance for Kidney Health looks forward to working with every member of the kidney community to create a world without kidney diseases. That work starts now.

Sincerely,

Mark E. Rosenberg, MD, FASN

Anupam Agarwal, MD, FASN
Mark E. Rosenberg, MD, FASN
President

Anupam Agarwal, MD, FASN
President-Elect

Susan E. Quaggin, MD, FASN
Councilor

David H. Ellison, MD, FASN
Councilor

Mark D. Okusa, MD, FASN
Past President

John R. Sedor, MD, FASN
Secretary-Treasurer

Barbara T. Murphy, MB BAO BCh, FRCPI
Councilor

Prabir Roy-Chaudhury, MD, PhD, FASN
Councilor
EXCELLENCE IN PATIENT CARE

Transforming Dialysis Safety
ASN’s partnership with the U.S. Centers for Disease Control and Prevention (CDC) completed its third contract year in July 2019. During this time, the initiative reached more than 1 million members of the kidney community and engaged with over 31,000 meeting participants, encouraging them to take the lead in the cultural change necessary to transform infection prevention in dialysis facilities. Nephrology Transforming Dialysis Safety (NTDS) is led by a Project Committee chaired by Alan S. Kliger, MD.

Key accomplishments include presentation of “Targeting Zero Infections: Human Factors Engineering and Its Application to Dialysis” (the sixth webinar in the Targeting Zero Infections series, Sept. 2019); issuance of hepatitis C testing recommendations; publication of a NephSAP special edition on infection prevention; partnership with Northwest Kidney Centers to present a Pop-Up Kidney Leadership Academy for the physician-nursing dyad (Oct. 2019); and development of recommendations for standardization of blood culture collection for patients receiving in-center hemodialysis.

In 2018, the contract with CDC was expanded to include the use of human factors engineering assessments to identify barriers to facility adherence to CDC-recommended infection prevention practices. To date, six site visits nationwide have been completed.

Future work will include additional webinars; an infection prevention curriculum for fellows; release of a guidance document on methods of preventing C. difficile transmission in outpatient dialysis; four human factors engineering observations, and the release of a final report; again, outside the scope of the CDC work. A pilot study of vascular access electronic checklists in seven outpatient dialysis units; and a continued presence at Kidney Week.

Putting Diabetic Kidney Disease in the Spotlight
In response to the recent development of new therapies for diabetic kidney diseases, ASN launched the Diabetic Kidney Disease Collaborative (DKD-C) in March 2019. With the reported results of CREDENCE, which demonstrated substantial kidney and cardiovascular benefits in patients with type 2 diabetes and DKD in addition to standard of care, ASN has prioritized efforts to educate the nephrology community and increase collaboration across specialties about the use of these life-changing therapies.
The DKD-C Task Force, which is led by ASN Councilor Susan E. Quaggin, MD, FASN, produced a call-to-action editorial and a policy-related editorial. The former strongly encourages SGLT2 inhibitor therapy in patients with type 2 diabetes using the inclusion criteria of CREDENCE. The latter recommends that public policy is needed to support a change in focus from kidney failure to kidney preservation.

The Task Force has developed a series of meetings that will include representatives from industry and stakeholders from other specialties to address key considerations and major questions about DKD as well as increase awareness, engagement, and excitement about the implementation of new therapies. These discussions will result in concrete recommendations for ensuring that people with diabetic kidney disease benefit from the new therapies. (The first conference in the series will be held in January 2020.)

**Improving AKI Care through AKI!Now**

ASN has partnered with Baxter Healthcare Corporation to build a foundational program to transform how AKI care is delivered, reduce its morbidity and mortality, and improve long-term outcomes, thus promoting recovery and reducing the incidence of kidney disease and failure.

To achieve these goals, the AKI!Now Steering Committee, chaired by Jorge Cerda, MD, MS, FASN, will study other AKI initiatives to determine knowledge gaps and potential areas of collaboration. During Kidney Week 2019, the Steering Committee convened with national and international experts to develop a Landscape Analysis, which revealed four key themes. Educational tools will be developed to assist a broad group of healthcare providers in identifying and managing high-risk populations using evidence-driven practices. These tools will target the medical community who first encounter AKI: nurses, physicians, primary care providers, advanced practice providers, and emergency room personnel. The AKI!Now initiative will hold its first webinar, on AKI recognition, in April 2020.

Early deliverables include the white paper “Identification and Management of AKI in High-Risk Populations” and a web-based compendium of the most up-to-date content on AKI available through ASN education and publications. Ideally, the web-based compendium will serve as a model for similar efforts in other areas, such as diabetic kidney disease. The compendium is scheduled to launch in July 2020.
Creating the Emergency Partnership Initiative
Natural disasters require wide-ranging and well-organized responses from medical organizations and volunteers. Post-emergency care of people with kidney diseases, notably those on dialysis, as well as people who suffer kidney injuries during disasters, requires special expertise.

In recognition of the need for an organized approach to the provision of this specialized care and services, ASN launched the Emergency Partnership Initiative (EPI). Nicole Lurie, MD, and Jeffrey I. Silberzweig, MD, serve as Advisory Committee Co-Chairs. Zaheeb Choudhry, MD, serves as Liaison, Caribbean Coalition. Initiative partners include representatives from dialysis provider organizations, suppliers, and United States government entities.

Under the direction of Dr. Lurie and Dr. Silberzweig, this initiative will address gaps in coordination and support of kidney-specific disaster care in the United States and Caribbean.
RESEARCH, DISCOVERY, AND INNOVATION

Launching KidneyX

KidneyX, the public-private partnership established between ASN and the U.S. Department of Health and Human Services (HHS), was created to accelerate the development of drugs, devices, biologics, and other therapies in the prevention, diagnosis, and treatment of kidney diseases. The KidneyX Steering Committee is chaired by John R. Sedor, MD, FASN.

In 2019, KidneyX received an overwhelming response of 165 submissions to its first prize, Redesign Dialysis Phase 1. Fifteen outstanding recipients were chosen to receive a prize of $75,000 each. These recipients were highlighted at the first KidneyX Summit held in April 2019. Two additional prizes were launched in the third quarter of 2019: Redesign Dialysis Phase 2 and the Patient Innovator Challenge. Recipients of these prizes will be announced in 2020.

KidneyX received a first-time Congressional appropriation of $5 million in early 2020. A historic accomplishment, ASN and bipartisan champions of KidneyX in Congress are seeking to build on this investment with another $25 million appropriation for KidneyX in Fiscal Year 2021. This appropriation would match private investment in the program, and would allow KidneyX to fulfill its mandate in the Executive Order on Advancing American Kidney Health to design the artificial kidney prize, launch prizes in other areas of diagnosis, prevention, and treatment, and to catalyze further private investment in KidneyX prize competition winners.

Expanding the Kidney Health Initiative’s Footprint

On January 1, 2019, Raymond C. Harris, MD, FASN, began his three-year term as ASN Co-Chair of the Kidney Health Initiative (KHI). Founded in September 2012, KHI continues to be the largest consortium in the kidney arena with more than 100 member organizations. As a public-private partnership with the U.S. Food and Drug Administration, KHI strives to catalyze innovation and the development of safe and effective patient-centered therapies for people with kidney diseases. KHI’s Seventh Annual Stakeholders Meeting focused on “Collaborating for Innovation to Improve Patient Care and Outcomes.”
Two supplements to the Technology Roadmap for Innovative Approaches to Renal Replacement Therapy were published in 2019: A Patient Edition to the Technology Roadmap for Innovative Approaches to Renal Replacement Therapy, and Fostering Innovations in Fluid Management. Both the roadmap and the supplements are valuable to the entire community, including the winners of KidneyX’s Redesign Dialysis contest.

KHI also published Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy, bringing the total number of publications to 17. The Kidney Pediatric Accelerator Trial Clearing House (Kidney-PATCH) was launched, in partnership with pediatric trial networks and organizations, to optimize planning for pediatric kidney disease clinical trials. KHI continues to support the community with 10 project workgroups, the newest titled “Building Capacity to Incorporate Patient Preferences into the Development of Innovative Alternatives to Renal Replacement Therapy (RRT)” and “Clinical Trial Design to Support Innovative Approaches to Renal Replacement Therapy.”

Renaming the ASN Foundation for Kidney Research
In July 2019, the ASN Foundation for Kidney Research launched a major rebranding initiative. The new name, KidneyCure, focuses all foundation efforts toward improving treatments and finding cures for the approximately 850 million people worldwide living with kidney diseases.

The foundation granted $3 million in support of 46 leading kidney researchers in 2019, including 27 new projects and 19 projects continuing from 2018. Established in 2012 by ASN, KidneyCure will continue funding current grant programs while exploring new avenues to support.

Cosponsoring APS Summer Kidney Research Conference
In June 2019, ASN cosponsored the American Physiological Society (APS)/ASN Conference: Control of Renal Function in Health and Disease (formerly the APS Renal Hemodynamics Summer Research Conference). The triennial conference “focuses on cutting-edge research presented by top investigators in the field of renal research.”

In addition to copresenting the conference, ASN provided travel support for 28 participants to attend the conference, underscoring the society’s continued commitment to expand opportunities for ASN members interested in basic, or fundamental, science.
ASN Kidney Week 2019 returned to Washington, DC, for the first time in more than 25 years. Held at the Walter E. Washington Convention Center, the meeting broke all previous attendance records with 14,384 participants, a 15% increase from the 2018 meeting in San Diego, CA. In 2019, Kidney Week received 4,856 total abstract submissions.

ASN introduced several additions to the meeting, including the Burton D. Rose, MD, Endowed Lecture, a Medical Educators Workshop, and the Basic Research Forum. Additionally, the meeting featured Hands-On Nephrology: A Workshop on Ultrasound-Guided Procedures and the Forum on the Executive Order on Advancing American Kidney Health. MOC points were also awarded for the first time at Kidney Week.

Tapping Kidney360 Editorial Team, Selecting NephSAP 3.0 Editorial Director

The new open access, online-only journal Kidney360 hired Michael Allon, MD, as editor-in-chief, with Luis A. Juncos, MD, FASN, and Mark A. Perazella, MD, FASN, serving as deputy editors. The peer-reviewed, general kidney journal started taking submissions in fall 2019 and began publishing in January 2020.

In April 2019, ASN announced the appointment of Alice M. Sheridan, MD, as the Editorial Director for NephSAP 3.0, with Martina M. McGrath, MBChB, FASN, serving as deputy editor. Dr. Sheridan will oversee the production of NephSAP beginning in January 2020. NephSAP is one of the most widely used educational programs in nephrology.
Maintaining High Rankings for *JASN, CJASN*

*JASN* remains the most cited nephrology journal publishing original research about the kidney and kidney disease. Under the leadership of Editor-in-Chief Josephine P. Briggs, MD, and a distinguished board of editors, *JASN* has continued its role as the flagship journal of nephrology with original articles, provocative perspectives, and important reviews. New this year is an Editorial Fellowship program that engages nine early career kidney researchers in the work of the journal.

*CJASN* continues to expand its offerings to the kidney community under the leadership of Editor-in-Chief Rajnish Mehrotra, MD, MBBS, FASN. Recent initiatives for trainees include the annual *CJASN* Trainee of the Year manuscript competition and the *CJASN* Trainee Reviewer Program, which educates early career researchers in mastering peer review. Both *JASN* and *CJASN* enjoyed successful sessions at Kidney Week 2019.

**Partnering with Renal Fellow Network**

ASN established a partnership with the Renal Fellow Network (RFN), an online forum where trainees can share posts that are open to the community to read and comment on. Currently led by Samira S. Farouk, MD, FASN, Sam Kant, MD, and Matthew A. Sparks, MD, FASN, RFN was one of the first nephrology blogs and was created by the late Nathan E. Hellman, MD, PhD, in 2008.

RFN has grown over the past decade from a personal blog to a rich source of easily accessible information for current and future nephrology trainees around the world. With more than 40,000 page views in July 2019, the RFN-ASN collaboration marks the beginning of an exciting new chapter for the website allowing RFN to continue to have a positive effect in nephrology education. Recurring series on the blog address high-yield topics for trainees including urine microscopy, kidney biopsy, landmark nephrology studies, interventional nephrology, kidney transplant, home hemodialysis, peritoneal dialysis, basic science, and pediatric nephrology. Published content also includes submissions from trainees and graduates.
Broadening ASN Communities, Social Media

ASN Communities’ outreach and impact continues to grow. Since Kidney Week 2018, there have been over 100,000 logins to Communities from 10,500 members from 115 countries, with 1,500 members using the free ASN Communities mobile app released in January 2019.

*In the Loop* now publishes weekly “Community Minded” summaries highlighting recent hot topics from Communities. In mid-2019, the AKI Community relaunched with one of the most popular discussions of the year: CRRT in the ICU. Popular discussions from the Open Forum included Calcium Channel Blockers, Uncontrolled Blood Pressure in an HD Patient, and Proteinuria/Nephrotic Syndrome in Pregnancy. At Kidney Week 2019, ASN Communities presented a poster, A Growing Thriving Online Educational Asset, informing attendees about how to leverage the collective knowledge of the Communities.

ASN’s social media presence continues its strong pattern of yearly growth. ASN’s main Twitter handle, @ASNKidney, experienced a 28% growth in followers since 2018; @ASNAdvocacy, @ASNkidney360, @KidneyNews, @JASN_News, @CJASN, and @Kidney_X experienced steady growth as well. In December 2018, the society launched a Twitter page for ASN’s newest online, open access journal Kidney360 (@ASNKidney360), set to debut in January 2020. ASN’s social media users are mostly from the United States, United Kingdom, Mexico, Canada, Spain, and India.

ASN’s share of voice dominated the kidney care category across both news and social media. In total, there were almost 6,000 direct mentions of ASN on news sites and social channels, reaching a combined unique monthly audience of 2.9 billion. The #KidneyWK hashtag alone was used more than 24,000 times—a 143% increase year over year.
LEADERSHIP DEVELOPMENT AND CULTURE CHANGE

Welcoming All
ASN membership shows continued growth. More than 21,000 kidney professionals over 130 countries now contribute to ASN as members. Since 2015, the society’s membership has grown 32%.

The second annual lesbian, gay, bisexual, transgender, and queer and questioning (LGBTQ) and ally member reception was held at Kidney Week 2019. The reception offers participants a venue for networking and gathering.

ASN hosted an invitational conference for Nephrology Division Chiefs in Dallas, TX, in June 2019. More than 35 adult and pediatric nephrology division chiefs from around the nation attended to discuss asserting the value of nephrology; physician productivity and compensation; financial support of educational efforts; recruitment, retention, diversity, and inclusion; and rightsizing training programs.

Establishing ASN Midcareer Awards, Continuing to Support Grants
ASN successfully launched the ASN Midcareer Awards Program, recognizing kidney health professionals between 10 and 20 years from completion of their professional training who have demonstrated impact in nephrology in the areas of patient care, research, education, mentorship, and leadership. The inaugural group of 10 recipients was honored during a plenary session at ASN Kidney Week 2019.

ASN partnered with the Robert Wood Johnson Foundation to administer the ASN-Harold Amos Medical Faculty Development Program (ASN-AMFDP) award. The second scholar, Rasheeda K. Hall, MD, MS, started her grant on August 1. Interviews were held in July 2019 to fund a new candidate for 2020. ASN expanded Kidney TREKS (Tutored Research and Education for Kidney Scholars) to include PhD students.

KidneyCure, the newly renamed ASN Foundation for Kidney Research, funds the Transition to Independence Grants Program (formerly the Career Development Grants Program), the Ben J. Lipps Research Fellowship Program, the William and Sandra Bennett Clinical Scholars Program, the ASN-AMFDP, and the ASN Pre-Doctoral Fellowship Program.
Setting New Directions for ASN’s Nephrology Fellow Survey, Data Subcommittee

The annual ASN Nephrology Fellow Survey successfully transitioned to a new principal investigator, Stephen M. Sozio, MD, FASN, who also chairs the ASN Data Subcommittee of the ASN Workforce and Training Committee. The subcommittee retooled the 2019 survey to include more pediatric nephrology-specific questions and mechanisms to more accurately assess a wider array of nephrologist practice patterns, including starting salaries and educational debt levels for new nephrologists.

The retooling also streamlined the process for participants, resulting in the survey’s best response rate (50%) since its inception in 2014. An analysis of survey results found the overall proportion of fellows recommending nephrology to medical students and residents has risen to 80%, an all-time high.

ASN has identified knowledge gaps and mechanisms to quantify them, such as assessing protected efforts for program directors’ educational activities. Future initiatives include assessments of the nephrology employment market and journey analyses to determine how programs can affect career trajectories.

Communicating New Understandings of Medical Career Choices

Insights from ongoing research collaborations with internal and external stakeholders were disseminated in several peer-reviewed articles. Results from the first phase of the ASN Best Practices Project—studying institutions graduating large numbers of future nephrologists—underscored the importance of exposure to clinical nephrology experiences and nephrology faculty contact to instilling interest in the specialty (American Journal of Nephrology, https://www.karger.com/Article/Pdf/501058).

Another paper examined influencing factors for specialty choice among late-stage medical students and residents. Across both cohorts, lack of interest in and exposure to nephrology, as well as perceptions about earning potential and work-life balance, were key in their choice to not pursue a nephrology career (BMC Nephrology, https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1289-y).
POLICY AND ADVOCACY

ASN worked with the White House and HHS to shape the components of the Advancing American Kidney Health (AAKH) initiative. The initiative established three objectives as official U.S. policy: 1) reduce the risk of kidney failure, 2) improve access to and quality of person-centered treatment options, and 3) increase access to kidney transplants.

To accomplish these goals, HHS has initiated efforts to launch a nationwide kidney disease public awareness campaign in partnership with ASN and the National Kidney Foundation, streamline kidney transplantation and increase the supply of organs, provide consideration for “requests for premarket approval of wearable or implantable artificial kidneys,” produce a strategy for encouraging innovation in new therapies through KidneyX, and develop payment models both to identify and treat at-risk populations earlier in kidney disease development and to increase home dialysis and kidney transplantation.

Securing Increased NIH Research Funding and Investing in Innovation through KidneyX

ASN’s advocacy efforts contributed to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) experiencing its first significant funding increase after more than a decade of flat budgets. The Fiscal Year (FY) 2020 appropriations package passed by Congress included substantial increases for the National Institutes of Health (NIH) and NIDDK: $41.86 billion for NIH and $2.1 billion for NIDDK. ASN also secured first-time Congressional funding for KidneyX, which will support KidneyX’s series of prize competitions accelerating innovative product development in areas of unmet need among people with kidney diseases and failure.

On July 10, 2019, President Donald J. Trump unveiled a much-anticipated new HHS-wide kidney care initiative called Advancing American Kidney Health (AAKH).
Advocating for Changes in Transplant Policy

ASN’s longtime policy priorities in transplantation saw significant movement. HHS released a report confirming the cost savings to Medicare that would result from extending coverage and an actuarial appraisal of a proposal to extend Medicare Part B and Part D coverage of immunosuppressive drugs for ESRD beneficiaries indefinitely.

Following these developments, the White House announced it would act on two of ASN’s policy priorities: improving the data used to evaluate Organ Procurement Organizations and removing financial barriers to living donation. ASN also supported efforts by Representative Jaime Herrera Beutler (R-WA) requesting that the U.S. Health Resources and Services Administration (HRSA) change its policy to allow the National Living Donor Assistance Center to reimburse lost wages and other non-travel expenses of living donors as currently permitted under the National Organ-Transplant Act of 1984.

Convening Kidney Health Advocacy and Kidney Community Advocacy Days

ASN convened the seventh annual Kidney Health Advocacy Day (KHAD) in Washington, DC, to urge Congress to fund and support legislation to improve care for kidney patients and accelerate innovation in kidney medicine. In partnership with the American Association of Kidney Patients (AAKP), 49 patient and physician advocates met during KHAD with nearly 100 congressional delegations about the urgent need to provide funding for KidneyX.

During Kidney Week 2019, patients and health professional organizations gathered for the fifth Kidney Community Advocacy Day to raise the profile of kidney health on Capitol Hill. On the heels of the historic Executive Order on Advancing American Kidney Health, advocates unified under a call for Congress to support the goals of the executive order and pass priority legislation of the kidney community, such as the Living Donor Protection Act and Immunosuppressive Drug Coverage Extension for Kidney Patients Act.
ASN AWARD RECIPIENTS

Lifetime Achievement Awards

Robert G. Narins Award
Mitchell H. Rosner, MD, FASN, received the 2019 Robert G. Narins Award for his outstanding contributions in nephrology education.

John P. Peters Award
Vicente E. Torres, MD, PhD, received the 2019 John P. Peters Award for his substantial nephrology research contributions and achievements in academic medicine.

Belding H. Scribner Award
Paul L. Kimmel, MD, FASN, received the 2019 Belding H. Scribner Award for his outstanding contribution to renal patient care.

Homer W. Smith Award
Toshiro Fujita, MD, PhD, FASN, received the 2019 Homer Smith Award for his outstanding research contributions which fundamentally affect the science of nephrology.

Donald W. Seldin Young Investigator Award
Samir M. Parikh, MD, FASN, received the 2019 Seldin Young Investigator Award for his outstanding record of achievement and creativity in basic and patient-oriented kidney research.

Midcareer Awards

Distinguished Clinical Service Award
Duuru Geetha, MD, FASN, and Jay L. Koyner, MD, received the 2019 Distinguished Clinical Service Award, which exemplifies excellence primarily in the delivery of patient care.

Distinguished Educator Award
Kambiz Kalantari, MD, MS, and Stephen M. Sozio, MD, FASN, received the 2019 Distinguished Educator Award, which honors individuals who have made substantial and meritorious contributions in clinical or research education.

Distinguished Leader Award
Deidra C. Crews, MD, MS, FASN, and Daniel E. Weiner, MD, MS, FASN, received the 2019 Distinguished Leader Award, which recognizes achievements in leadership by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality of care for patients.

Distinguished Mentor Award
Tamara Isakova, MD, and Michal L. Melamed, MD, received the 2019 Distinguished Mentor award, which honors individuals who have made contributions to the kidney community through the mentorship and development of other clinicians or researchers.
Distinguished Researcher Award
Laurence H. Beck, Jr., MD, PhD, and David Cherney, MD, PhD, received the 2019 Distinguished Researcher Award, which acknowledges individuals who have made substantial research contributions to the discipline of nephrology.

ASN President’s Medal
ASN awards the President’s Medal to individuals who have helped advance ASN’s mission. The recipients of the 2019 President’s Medal are all officials in the U.S. Department of Health and Human Services:

- Alex M. Azar II, Secretary
- Eric D. Hargan, Deputy Secretary
- Seema Verma, Administrator, Centers for Medicare and Medicaid Services
- Ed Simcox, Chief Technology Officer
- ADM Brett P. Giroir, MD, Assistant Secretary for Health
- James Parker, Senior Advisor to the Secretary
- Nick Uehlecke, Advisor
- Sandeep Patel, PhD, Open Innovation Manager
- Murray Sheldon, MD, FDA CDRH, Associate Director of Innovation and Technology
- Adam Boehler, Former Deputy Administrator for Innovation Policy and Director, Center for Medicare & Medicaid Innovation
- Abe Sutton, Former Advisor and White House staff

ASN is honored to have had more than 200 kidney professionals volunteer on 17 key committees in 2019. It is through the steadfast commitment of our volunteers and staff that we continue to deliver on our mission and promise.

- Award Selection Committee
- Career Advancement Committee
- Continuous Professional Development Committee
- Diversity and Inclusion Committee
- Ethics and Professional Standards Committee
- Executive Committee
- Grants Review Committee
- Investment Committee
- Media and Communications Committee
- Nominating Committee
- Policy and Advocacy Committee
- Postgraduate Education Committee
- Program Committee
- Publications Committee
- Quality Committee
- Workforce and Training Committee
- Young Investigator Award Selection Subcommittee
Grant Program: Transition to Independence
Recipient: Tomokazu Souma, MD, PhD
Project Title: Harnessing Antioxidative Stress Pathways in Renal Epithelial Progenitors To Prevent AKI-to-CKD Transition

HOW WOULD YOU SUM UP YOUR RESEARCH IN ONE SENTENCE?
My research primarily focuses on understanding cellular stress adaptive pathways in kidneys with the ultimate goal to harness these pathways for therapeutic uses to prevent kidney disease progression in patients.

PROVIDE A BRIEF OVERVIEW OF THE RESEARCH YOU WILL CONDUCT WITH HELP FROM THE GRANT.
The goal of my project is to investigate the functions of antioxidative stress pathways in the transition of acute kidney injury (AKI) to chronic kidney disease (CKD). We will use multiple transgenic mouse lines to address this research aim.

WHAT INSPIRED YOU TO FOCUS YOUR RESEARCH IN THIS AREA?
The kidney has always been my favorite organ to study. I was fascinated when I first learned the beautiful structure and functions of kidneys. I cannot forget the excitement I got when I observed the intricate network of renal erythropoietin-producing cells. My prior clinical and research training has inspired me and guided me to focus on the cellular stress adaptation pathways in kidneys.

WHAT ARE THE MAJOR CHALLENGES FACING NEPHROLOGY RESEARCH TODAY?
The current technological advancements are so rapid and transformative. However, partly based on the complexity of renal structure and function, we have not utilized the newest revolutionizing technologies well. Multidisciplinary collaboration with scientists in other fields would facilitate our discoveries.

WHAT HAS SURPRISED YOU MOST ABOUT YOUR CAREER?
I have been so fortunate to meet multiple great scientists throughout my early career. All the encounters shaped my career path and provided me incredible opportunities. I would like to thank Dr. Mitchell Halperin, Dr. Susan Quaggin, Dr. Myles Wolf, Dr. Jing Jin, Dr. Brigid Hogan, Dr. Masayuki Yamamoto, and my excellent colleagues.

WHAT ADVICE WOULD YOU GIVE TO OTHERS TO ENCOURAGE THEM TO APPLY FOR THIS GRANT FUNDING?
This is an excellent mechanism for supporting early career investigators in nephrology toward research independence. I encourage all eligible early career scientists to apply for this prestigious award.
Established in 2012, KidneyCure provides $3 million annually to fund the ASN Pre-Doctoral Fellowship Program, the Ben J. Lipps Research Fellowship Program, the Transition to Independence Grants Program, the William and Sandra Bennett Clinical Scholars Program, and the American Society of Nephrology-Harold Amos Medical Faculty Development Program Award.

KidneyCure congratulates the talented group of researchers and educators who were awarded grants in 2019.

**Transition to Independence Grants Program**
The program invests $100,000 a year per investigator for two years to foster independent research careers and ensure a pipeline of innovative research in the field of nephrology. The Transition to Independence Grants Program is supported by contributions provided by ASN, Akebia Therapeutics, Amgen, and individual donors.

**Carl W. Gottschalk Award Recipients**

Subhashini Bolisetty, PhD  
University of Alabama at Birmingham  
*Targeting Ferritin in Sepsis-Associated Acute Kidney Injury*

Louise Evans, PhD  
University of Minnesota  
*Pathological Role of T-Cells in Salt-Sensitive Hypertension*

Naoka Murakami, MD, PhD  
Brigham and Women’s Hospital  
*Roles of Immune Checkpoint Signaling in Autoimmune Kidney Diseases*

Sagar Nigwekar, MD, MMSc  
Massachusetts General Hospital  
*Novel Determinants of Calcific Uremic Arteriolopathy*
Carl W. Gottschalk Award Recipients (continued)

Tengis Pavlov, PhD
Henry Ford Health System
Mechanism and Role of ATP Release in Polycystic Kidney Diseases

Tomokazu Souma, MD, PhD
Duke University
Harnessing Antioxidative Stress Pathways in Renal Epithelial Progenitors to Prevent AKI-to-CKD Transition

(Not Pictured)

Fahad Saeed, MD
University of Rochester
Pilot Testing of a Communication Intervention to Promote Shared Renal Replacement Therapy Decision Making in Older Patients with Chronic Kidney Disease (RRT-SDM Trial)

John Merrill Grant in Transplantation Recipient

Sarah Panzer, MD
University of Wisconsin Madison
Impact of B Cell Survival Cytokines on Transplant Glomerulopathy
Norman Siegel Research Scholar Grant Recipient

Brian Becknell, MD, PhD
The Research Institute at Nationwide Children's Hospital
Therapeutic Urothelial Remodeling: A Novel Strategy to Limit Obstructive Kidney Injury

Oxalosis and Hyperoxaluria Foundation (OHF)-KidneyCure Grant Recipient

Dylan Dodd, MD, PhD
Stanford University
Gut Microbiota Modulation of Oxalate
Ben J. Lipps Research Fellowship Program

The Ben J. Lipps Research Fellowship Program supports nephrology fellows who will advance the understanding of kidney biology and disease and is fully endowed by contributions provided by Fresenius Medical Care, ASN, the American Renal Patient Care Foundation, Inc., Amgen, Baxter, and the PKD Foundation. The program distributes $50,000 a year per fellow for two years.

Ben J. Lipps Research Fellows

Lakshmi Ganesan, MD, MAS
Stanford University
Pediatric Peritoneal Dialysis and Uremic Solutes

Kana Miyata, MD
University of Montreal Hospital Research Center
Novel Role of Heterogeneous Nuclear Ribonucleoprotein F (hnRNP F) in Regulation of Sodium-Glucose Cotransporter 2 (SGLT2) Expression in Diabetes

Nabin Poudel, PhD
University of Virginia
Pannexin1 and Acute Kidney Injury

Katherine Scovner, MD
Brigham and Women’s Hospital
Acid-Base Status of Hospitalized Patients on Maintenance Hemodialysis as a Predictor of Hospital Outcomes

Seyedmohammad Ebrahim Tahaei, PhD
University of Maryland, Baltimore
Illuminating the Mechanisms that Control Salt Balance in the Face of NCC Inhibition
Sri Lekha Tummalapalli, MD, MBA
University of California, San Francisco
Screening Strategies for Chronic Kidney Disease in US Populations

George B. Rathmann Research Fellow
Michael Holliday, Jr., MD, PhD
Baylor College of Medicine
From Bedside to Bench: Gramoxone and Mesoamerican Nephropathy

Jared J. Grantham Research Fellow
Ken Sutha, MD, PhD
Lucille Packard Children’s Hospital
Patient-Derived Kidney Organoids

Donald E. Wesson Research Fellow
Xiao-Tong Su, PhD
Oregon Health and Science University
Dietary Potassium Causes Chloride-Induced Distal Hypertension

Aneta Przepiorski, PhD
University of Pittsburgh
Modeling Kidney Fibrosis and Testing Therapeutic Compounds in Human Kidney Organoids
William and Sandra Bennett Clinical Scholars Grant Program
The William and Sandra Bennett Clinical Scholars Program provides funding to clinician educators to conduct a project to advance all facets of nephrology education and teaching. The program provides $50,000 a year for two years to one recipient annually.

(Not Pictured)
Tushar Chopra, MBBS, FASN
University of Virginia
Peritoneal Dialysis (PD) Curriculum Development to Improve PD Prescription Writing Amongst Nephrology Trainees

American Society of Nephrology-Harold Amos Medical Faculty Development Program
The ASN-Harold Amos Medical Faculty Development Program aims to increase diversity among future leaders in nephrology by supporting the research and career development of a kidney scholar and future healthcare leader from a historically disadvantaged background.

Rasheeda Hall, MD, MS
Duke University
Establishing Evidence to Manage Geriatric Syndromes in Hemodialysis Patients
ASN Pre-Doctoral Fellowship Program
The ASN Pre-Doctoral Fellowship Program provides $10,000 a year per recipient for two years to early career-stage PhD students to conduct original research projects and make contributions to the understanding of kidney biology and disease.

Benjamin Bowe
St. Louis VA Health Care System
Identification of Inpatient Acute Kidney Injury and Phenotypes Using Large Scale Electronic Medical Records

Yijiang Chen
Case Western Reserve University
Computational Pathology Approach for Characterizing Kidney Biopsies and Predicting APOL1 Risk Variants

Pei-Ju Liu
SUNY Upstate Medical University
The Role of Myo1e- and Clathrin-Dependent Endocytic Trafficking in Podocyte Health and Disease

Franco Puleo
Boston University
Sympathetic Nervous System Regulation of the NCC in Salt Sensitive Hypertension

Annie Ryan
UT Southwestern Medical Center
Elucidating Vascular Signals in Nephron Formation Using Human Organoids
FOUNDERS CIRCLE MEMBERS

KidneyCure gratefully acknowledges our Founders Circle Members for their generous contributions. With the help of our Founding Members, KidneyCure is making great strides in supporting the next generation of nephrology clinicians, researchers, and educators who will fuel innovation and translate findings into improved quality of life for patients.

Transition to Independence Grants Program Donors

- **ASN**
  - American Society of Nephrology
  - $15,000,000

- **Akebia Therapeutics**
  - $1,000,000

Ben J. Lipps Research Fellowship Program Donors

- **Fresenius Medical Care**
  - $10,000,000

- **ASN**
  - $6,500,000

- **American Renal Associates**
  - $1,000,000

- **Amgen**
  - $1,000,000

- **Baxter**
  - $1,000,000

- **PKD Foundation**
  - Polycystic Kidney Disease
  - $500,000
KIDNEYCURE SUPPORTERS

Visionary Circle
The Visionary Circle recognizes individuals who have donated, pledged, or made a bequest of $75,000 or more to the foundation or its programs.

Bob Alpern and Pat Preisig
William and Sandra Bennett
Jonathan and Deb Himmelfarb
Paula Messenheimer and Ray Harris
William E. Mitch and Alexandra F. Mitch

Securing the Future Campaign Donors
Donations to the Securing the Future Campaign support efforts to endow the Transition to Independence Grants Program.

Industry
Akebia Therapeutics
Amgen

Benefactors ($50,000+)
Mark D. Okusa and Diane L. Rosin Okusa
Ambra Pozzi and Roy Zent

Patrons ($25,000+)
Sharon Anderson
Tomas Berl
Joseph V. Bonventre
Linda and Tom DuBose
William and Mary Henrich
Thomas H. Hostetter
Allison and Tod Ibrahim
Sharon and John Moe
Barbara T. Murphy
Prabir Roy-Chaudhury
Paul W. Sanders
John Sedor and Geri Presti
Wanda and Donald E. Wesson

Advocates ($10,000+)
Anupam Agarwal and Lisa M. Curtis
Deidra C. Crews
The Hakim Family Fund
Eleanor D. Lederer
Julie Lin and Frank S. David
Rajnish Mehta
Susan E. Quaggin
John R. and Margaret Duffey Raymond
Matthew R. Weir
Jerry Yee

Friends (under $5,000)
Jeffrey H. Miner
Bruce and Karen Molitoris
Uptal Patel
Mark Rosenberg and Monica Overkamp
Detlef O. Schlondorff
C. Craig and Audrae Tisher
The Virginia and Warren Stone Fund held by Vanguard Charitable

Friends (under $5,000)
Matthew K. Abramowitz
Pilar A. Acuña
Nancy Day Adams & Thomas D. Sinsteden
Seth L. Alper
Candice Aranjo
George P. Bayliss
Laurence H. Beck, Jr.
Sara E. Bloom Leedes
Steven C. Borkan
The Brimmage Family
Marcus L. Britton
Michael Butterworth
Mary Ann Cameron
Emily Campbell
Campbell Supply Parts Department
Euan J. F. Carlisle
Len and Marsha Charney
Ling Chow
Ted K. Chow
David M. Clive
Neera K. Dahl
Ginny Darakjian
Mohapatra Zafreen Davids
Michelle Denburg
Paul E. Drawz
Tarek M. El-Achkar
Mary Fischer
Michael J. Fischer
Agnes Fogo
John R. Fontanilla
Ron Fox
Hirotaka Fukasawa
Jack Gerlach
Rose Giannmarco
Jake Gilbreath
David S. Goldfarb
Manjula Gowrishankar
Camille Gregory
Charles J. Griffee
Nadja Grobe
Susan B. Gurley
Francis Hao
Dennis Harris
Anne Hay
J. H. Helderman
Ann B. Henderson
LaTonya J. Hickson
Melinda Hockensmith
Chi-yuan Hsu
Benjamin D. Humphreys
Jula K. Inrig
Madison Jechow
Michelle A. Josephson
Bruce A. Julian
Pinelopi P. Kapitsinou
Anil K. Karhaloo
Akira Kato
Alfred Hyoungj Kim
Susan Kirk
Thomas R. Kleyman
Donald Kuenzeler
Margaret Laing
Mary W. Landreth
Pascale Hammond Lane
David E. Leaf
Timmy C. Lee
Sanna H. Lehtonen
Trudi & Stuart Linas
Peter G. Linde
Michael S. Lipkowitz
Marianne and Dietmar Lippmann
Robert G. Luke
Peter Magner
Mallinckrodt Pharmaceuticals
Annual Fund Donors

Annual fund donors contributed to general foundation activities in 2019.

Industry
Horizon Therapeutics

Donors
Alper Lab (fund held by Schwab Charitable)
Peter S. Aronson
Janet and Arthur Atlas
Mounita Barua
Daniel Batlle
Laurence H. Beck, Jr.
Jacqueline M. Benson
Arnold S. Berns
Patty Boas
Vincent Bonventre
Susan Brain
Josephine P. Briggs
Frank C. Brosius, III
Clemens D. Cohen
Marilyn L. Cohen
Alfred Charles Cottrell, Jr.
David H. Ellison
Kevin John Fowler
(The Voice of the Patient)

Miguel Angelo Goes
Diane Greenley
Robert Hamilton
Stephen D. Haymes
Sandra Herrmann
Jamie S. Hirsch
Thomas H. Hostetter
Benjamin D. Humphreys
Kelly A. Hyndman
J.T. Shulman & Company, P.C.
Jane Johnston
Mae Karwowski
Leslie Kirschenbaum
Thomas and Barbara Kleyman
Edgar V. Lerma
Robert G. Luke
Markle Gift Fund held by Fidelity Charitable
Sharon M. Moe
Patricia A. and Jeremiah J. Morrissey
Rachel Muir

Hal Nesbitt
Kara Page
Paul M. Palevsky
Bhasker Patel
Roslynn Patterson
Nick Raschella
Isabel Roberti
Melanie Robey
Michael J. Ross
David J. Salant
Julia J. Scialla
Diane K. Shah
Barry H. Smith
Matthew A. Sparks
Robert F. Spurney
Joseph Stella
UConn Nephrology Family
Samir and Mary Lou Wahby
Tamara Watkins
Charlotte Wise
Mark Zurack
Anonymous (4)
CONSOLIDATED
Net Assets, Liabilities, and Investments

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Liabilities</td>
<td>$9,666,712</td>
<td>$8,962,339</td>
<td>$8,972,244</td>
<td>$10,308,147</td>
<td>$10,673,245</td>
</tr>
<tr>
<td>Total Net Assets</td>
<td>$118,573,581</td>
<td>$99,645,276</td>
<td>$104,606,161</td>
<td>$87,691,111</td>
<td>$77,561,417</td>
</tr>
<tr>
<td>Total Liabilities and</td>
<td>$128,240,293</td>
<td>$108,607,615</td>
<td>$113,578,405</td>
<td>$97,999,258</td>
<td>$88,234,662</td>
</tr>
<tr>
<td>Net Assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Investments</td>
<td>$116,292,400</td>
<td>$93,297,021</td>
<td>$99,151,805</td>
<td>$84,107,568</td>
<td>$74,138,196</td>
</tr>
</tbody>
</table>

Monitoring the ratio of expenses to investments is critical in supporting the organization's continued growth and preserving the organization's stable financial health.
### Financial Snapshot 2010–2019

<table>
<thead>
<tr>
<th></th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Revenue</strong></td>
<td>$18,553,510</td>
<td>$18,472,188</td>
<td>$19,412,239</td>
<td>$20,586,347</td>
<td>$20,791,852</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$17,263,753</td>
<td>$18,011,418</td>
<td>$17,764,491</td>
<td>$15,954,195</td>
<td>$16,680,177</td>
</tr>
<tr>
<td><strong>Net</strong></td>
<td>$1,289,757</td>
<td>$460,770</td>
<td>$1,647,748</td>
<td>$4,632,152</td>
<td>$4,111,675</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>$12,166,749</td>
<td>$12,692,878</td>
<td>$11,950,610</td>
<td>$11,076,846</td>
<td>$10,618,659</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td>$44,460,455</td>
<td>$43,214,638</td>
<td>$49,206,628</td>
<td>$70,506,984</td>
<td>$75,338,984</td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td>$56,627,204</td>
<td>$55,907,516</td>
<td>$61,157,238</td>
<td>$81,583,830</td>
<td>$85,957,643</td>
</tr>
</tbody>
</table>
### Membership Growth 2010–2019

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenue</td>
<td>$18,553,510</td>
<td>$18,472,188</td>
<td>$19,412,239</td>
<td>$20,586,347</td>
<td>$20,791,852</td>
<td>$22,802,006</td>
<td>$25,588,532</td>
<td>$24,156,447</td>
<td>$21,456,666</td>
<td>$26,583,114</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>$17,263,753</td>
<td>$18,011,418</td>
<td>$17,764,491</td>
<td>$15,954,195</td>
<td>$16,680,177</td>
<td>$17,297,439</td>
<td>$18,645,417</td>
<td>$19,235,442</td>
<td>$21,456,666</td>
<td>$26,538,207</td>
</tr>
<tr>
<td>Net</td>
<td>$1,289,757</td>
<td>$460,770</td>
<td>$1,647,748</td>
<td>$4,632,152</td>
<td>$4,111,675</td>
<td>$5,504,567</td>
<td>$6,943,177</td>
<td>$4,921,005</td>
<td>$4,011,835</td>
<td>$2,424,907</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>$12,166,749</td>
<td>$12,692,878</td>
<td>$11,950,610</td>
<td>$11,076,846</td>
<td>$10,618,659</td>
<td>$10,673,245</td>
<td>$10,308,147</td>
<td>$8,972,244</td>
<td>$8,962,339</td>
<td>$9,666,712</td>
</tr>
<tr>
<td>Total Liabilities and Net Assets</td>
<td>$56,627,204</td>
<td>$55,907,516</td>
<td>$61,157,238</td>
<td>$81,583,830</td>
<td>$85,957,643</td>
<td>$88,234,662</td>
<td>$97,999,258</td>
<td>$113,578,405</td>
<td>$108,607,615</td>
<td>$128,240,293</td>
</tr>
</tbody>
</table>
ASN SOURCES OF REVENUE

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Education</td>
<td>59%</td>
<td>57%</td>
<td>62%</td>
<td>63%</td>
<td>61%</td>
<td>61%</td>
</tr>
<tr>
<td>Communications</td>
<td>18%</td>
<td>21%</td>
<td>20%</td>
<td>22%</td>
<td>23%</td>
<td>22%</td>
</tr>
<tr>
<td>Membership</td>
<td>15%</td>
<td>14%</td>
<td>13%</td>
<td>19%</td>
<td>21%</td>
<td>22%</td>
</tr>
<tr>
<td>Other</td>
<td>1%</td>
<td>2%</td>
<td>—</td>
<td>1%</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td>KHI</td>
<td>4%</td>
<td>3%</td>
<td>4%</td>
<td>2%</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>NTDS</td>
<td>3%</td>
<td>3%</td>
<td>1%</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

2019
### ASN Sources of Expenses

#### 2019

- **Education**: 35%
- **Communications**: 17%
- **Other**: 29%
- **Policy**: 6%
- **KHI**: 3%
- **NTDS**: 2%
- **Membership**: 2%
- **KX**: 6%

#### ASN Sources of Expenses by Category

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Education</td>
<td>35%</td>
<td>37%</td>
<td>45%</td>
<td>43%</td>
<td>48%</td>
<td>48%</td>
</tr>
<tr>
<td>Communications</td>
<td>18%</td>
<td>18%</td>
<td>22%</td>
<td>23%</td>
<td>22%</td>
<td>25%</td>
</tr>
<tr>
<td>Other</td>
<td>29%</td>
<td>29%</td>
<td>21%</td>
<td>22%</td>
<td>19%</td>
<td>19%</td>
</tr>
<tr>
<td>Policy</td>
<td>6%</td>
<td>6%</td>
<td>4%</td>
<td>5%</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Membership</td>
<td>2%</td>
<td>2%</td>
<td>2%</td>
<td>2%</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>KHI</td>
<td>5%</td>
<td>6%</td>
<td>4%</td>
<td>5%</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>NTDS</td>
<td>3%</td>
<td>2%</td>
<td>2%</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>KX</td>
<td>2%</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>
# ORGANIZATIONAL SNAPSHOT

American Society of Nephrology and the ASN Foundation for Kidney Research consolidated statements of financial position.

<table>
<thead>
<tr>
<th>Assets</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>$4,970,055</td>
<td>$4,964,808</td>
</tr>
<tr>
<td>Accounts receivable, net</td>
<td>$640,604</td>
<td>$1,199,280</td>
</tr>
<tr>
<td>Grant receivable</td>
<td>$300,000</td>
<td>$500,000</td>
</tr>
<tr>
<td>Pledges receivable, net</td>
<td>$635,394</td>
<td>$482,238</td>
</tr>
<tr>
<td>Investments</td>
<td>$116,292,400</td>
<td>$93,297,021</td>
</tr>
<tr>
<td>Prepaid expenses and deposits</td>
<td>$625,710</td>
<td>$649,684</td>
</tr>
<tr>
<td>Property held for sale</td>
<td>—</td>
<td>$7,294,102</td>
</tr>
<tr>
<td>Property and Equipment, net</td>
<td>$4,776,130</td>
<td>$220,482</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$128,240,293</strong></td>
<td><strong>$108,607,615</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$2,478,400</td>
<td>$1,369,406</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>$3,149,248</td>
<td>$3,427,059</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>$4,039,064</td>
<td>—</td>
</tr>
<tr>
<td>Interest rate swap agreement</td>
<td>—</td>
<td>$54,179</td>
</tr>
<tr>
<td>Tax exempt bond</td>
<td>—</td>
<td>$4,111,695</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$9,666,712</strong></td>
<td><strong>$8,962,339</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net Assets</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions</td>
<td>$117,938,187</td>
<td>$99,163,038</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>$635,394</td>
<td>$482,238</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$118,573,581</strong></td>
<td><strong>$99,645,276</strong></td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>$128,240,293</strong></td>
<td><strong>$108,607,615</strong></td>
</tr>
</tbody>
</table>
Income Statement

<table>
<thead>
<tr>
<th>Revenue Sources (% of total)</th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership Dues</td>
<td>12.6%</td>
<td>16.1%</td>
<td>15.0%</td>
<td>13.7%</td>
<td>14.1%</td>
</tr>
<tr>
<td>Government Grants</td>
<td>1.0%</td>
<td>2.0%</td>
<td>4.1%</td>
<td>3.1%</td>
<td>1.7%</td>
</tr>
<tr>
<td>All other grants and contributions</td>
<td>0.2%</td>
<td>0.60%</td>
<td>4.63%</td>
<td>2.0%</td>
<td>3.9%</td>
</tr>
<tr>
<td>Corporate Support</td>
<td>17.0%</td>
<td>16.9%</td>
<td>16.0%</td>
<td>17.3%</td>
<td>19.4%</td>
</tr>
<tr>
<td>Program Services Revenue</td>
<td>69.2%</td>
<td>64.4%</td>
<td>60.3%</td>
<td>63.9%</td>
<td>60.9%</td>
</tr>
</tbody>
</table>

Expenses

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Expenses</td>
<td>$26,538,207</td>
<td>$24,139,293</td>
<td>$22,063,996</td>
<td>$21,070,612</td>
<td>$19,759,900</td>
</tr>
<tr>
<td>Growth Rate %</td>
<td>9.9%</td>
<td>9.4%</td>
<td>4.7%</td>
<td>6.6%</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Personnel</td>
<td>$9,297,687</td>
<td>$8,255,991</td>
<td>$6,860,007</td>
<td>$5,777,972</td>
<td>$4,983,158</td>
</tr>
<tr>
<td>Growth Rate %</td>
<td>12.6%</td>
<td>20.3%</td>
<td>18.7%</td>
<td>16.0%</td>
<td>1.9%</td>
</tr>
</tbody>
</table>

Profitability

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in Unrestricted Net Assets</td>
<td>$18,979,500</td>
<td>$(4,543,324)</td>
<td>$16,915,050</td>
<td>$10,129,694</td>
<td>$2,222,433</td>
</tr>
<tr>
<td>As % of Expenses</td>
<td>17.5%</td>
<td>-18.8%</td>
<td>76.7%</td>
<td>48.1%</td>
<td>11.2%</td>
</tr>
<tr>
<td>Growth Rate %</td>
<td>19.0%</td>
<td>-4.3%</td>
<td>19.3%</td>
<td>13.1%</td>
<td>2.9%</td>
</tr>
</tbody>
</table>

Balance Sheet

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>$4,970,055</td>
<td>$4,964,808</td>
<td>$3,968,656</td>
<td>$3,420,812</td>
<td>$4,866,312</td>
</tr>
<tr>
<td>Investment</td>
<td>$116,292,400</td>
<td>$93,297,021</td>
<td>$99,151,805</td>
<td>$84,107,568</td>
<td>$74,138,196</td>
</tr>
<tr>
<td>Gross land, buildings, and equipment</td>
<td>$4,776,130</td>
<td>$152,150</td>
<td>$7,665,786</td>
<td>$7,957,988</td>
<td>$8,136,584</td>
</tr>
<tr>
<td>Liabilities as % of assets</td>
<td>7.5%</td>
<td>8.3%</td>
<td>7.9%</td>
<td>10.5%</td>
<td>12.1%</td>
</tr>
<tr>
<td>Total unrestricted net assets</td>
<td>$128,240,293</td>
<td>$108,607,615</td>
<td>$113,578,405</td>
<td>$87,691,111</td>
<td>$77,561,417</td>
</tr>
</tbody>
</table>

Liquidity

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Months of Cash</td>
<td>2.2</td>
<td>2.5</td>
<td>2.2</td>
<td>1.9</td>
<td>3.0</td>
</tr>
<tr>
<td>Months of Cash and Investments</td>
<td>54.8</td>
<td>48.8</td>
<td>56.1</td>
<td>49.8</td>
<td>48.0</td>
</tr>
</tbody>
</table>
The ASN Corporate Support Program recognizes supporters year-round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney diseases. ASN gratefully acknowledges the following companies and organizations for their contributions in 2019.

**DIAMOND LEVEL**

- AstraZeneca
- Baxter
- Fresenius Medical Care
- Orelypsa
- TRICIDA

**PLATINUM LEVEL**

- Alexion
- Mallinckrodt Pharmaceuticals
- Otsuka
- REATA Pharmaceuticals

**GOLD LEVEL**

- Akebia Therapeutics
- Amgen
- Janssen Pharmaceuticals, Inc.
- OPKO Pharmaceuticals, LLC
- Retrophin, Inc.

**BRONZE LEVEL**

- Amicus Therapeutics
- Cara Therapeutics
- Daiichi Sankyo, Inc.
- GSK
- KDIGO
- Rockwell Medical
- Sanofi Genzyme
A world without kidney diseases